Pharmaceutical Executive
Affiris struck a deal with GlaxoSmithKline to develop two Alzheimer's treatments. As part of the agreement, GSK gains a fancy protein technology that could be a boon for future molecules.
Pharmaceutical Executive-10-29-2008
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
